Literature DB >> 23590772

Coagulation abnormalities in osteonecrosis and bone marrow edema syndrome.

Patrick Orth1, Konstantinos Anagnostakos.   

Abstract

The aim of this review was to provide information about the variety of thrombophilic and hypofibrinolytic markers that are possible risk factors for the development of osteonecrosis and bone marrow edema syndrome. A total of 48 parameters were identified in 45 studies that included 2163 patients. The most frequently reported laboratory findings included altered serum concentrations of lipoproteins, decreased concentration and function of fibrinolytic agents, increased levels of thrombophilic markers, and several single nucleotide polymorphisms. Despite inhomogeneities in reported parameters, results, patients' collectives, and treatment strategies, these data suggest that coagulation abnormalities may play an important role in the emergence of osteonecrosis and bone marrow edema syndrome. Copyright 2013, SLACK Incorporated.

Entities:  

Mesh:

Year:  2013        PMID: 23590772     DOI: 10.3928/01477447-20130327-08

Source DB:  PubMed          Journal:  Orthopedics        ISSN: 0147-7447            Impact factor:   1.390


  11 in total

Review 1.  The role of autophagy in steroid necrosis of the femoral head: a comprehensive research review.

Authors:  Pan Luo; Fuqiang Gao; Jun Han; Wei Sun; Zirong Li
Journal:  Int Orthop       Date:  2018-05-25       Impact factor: 3.075

2.  Effects of intravenous iloprost therapy in patients with bone marrow oedema of the foot and ankle.

Authors:  Eric Röhner; Timo Zippelius; David Steindl; Jasmin Fussi; Carsten Perka
Journal:  Eur J Orthop Surg Traumatol       Date:  2013-09-19

3.  Percutaneous Drilling for Early-Stage Osteonecrosis About the Ankle.

Authors:  Bradley M Lamm; Kimona Issa; Bhaveen H Kapadia; Qais Naziri; Lynne C Jones; Michael A Mont
Journal:  JBJS Essent Surg Tech       Date:  2014-11-12

4.  Long term anticoagulation (4-16 years) stops progression of idiopathic hip osteonecrosis associated with familial thrombophilia.

Authors:  Charles J Glueck; Richard A Freiberg; Robert Wissman; Ping Wang
Journal:  Adv Orthop       Date:  2015-01-29

5.  Enoxaparin prevents steroid-related avascular necrosis of the femoral head.

Authors:  Rainer Beckmann; Hayfaa Shaheen; Nisreen Kweider; Alireza Ghassemi; Athanassios Fragoulis; Benita Hermanns-Sachweh; Thomas Pufe; Mamed Kadyrov; Wolf Drescher
Journal:  ScientificWorldJournal       Date:  2014-07-02

6.  Case report: primary osteonecrosis associated with thrombophilia-hypofibrinolysis and worsened by testosterone therapy.

Authors:  Michael Ian Jarman; Kevin Lee; Ariel Kanevsky; Sarah Min; Ilana Schlam; Chris Mahida; Ali Huda; Alexander Milgrom; Naila Goldenberg; Charles J Glueck; Ping Wang
Journal:  BMC Hematol       Date:  2017-03-27

7.  The impact of high total cholesterol and high low-density lipoprotein on avascular necrosis of the femoral head in low-energy femoral neck fractures.

Authors:  Xianshang Zeng; Ke Zhan; Lili Zhang; Dan Zeng; Weiguang Yu; Xinchao Zhang; Mingdong Zhao; Zhicheng Lai; Runzhen Chen
Journal:  J Orthop Surg Res       Date:  2017-02-17       Impact factor: 2.359

8.  Combined Treatment with an Anticoagulant and a Vasodilator Prevents Steroid-Associated Osteonecrosis of Rabbit Femoral Heads by Improving Hypercoagulability.

Authors:  Fang Cao; Ge Liu; Wei Wang; Benjie Wang; Xiaowei Wei; Faqiang Lu; Fan Yang; Kai Kang; Yongxuan Wang; Jiahui Yang; Kairong Qin; Dewei Zhao
Journal:  Biomed Res Int       Date:  2017-10-19       Impact factor: 3.411

Review 9.  Osteonecrosis of the Femoral Head in Patients with Hypercoagulability-From Pathophysiology to Therapeutic Implications.

Authors:  Elena Rezus; Bogdan Ionel Tamba; Minerva Codruta Badescu; Diana Popescu; Ioana Bratoiu; Ciprian Rezus
Journal:  Int J Mol Sci       Date:  2021-06-24       Impact factor: 5.923

10.  Increased COUP-TFII Expression Mediates the Differentiation Imbalance of Bone Marrow-Derived Mesenchymal Stem Cells in Femoral Head Osteonecrosis.

Authors:  Sheng-Hao Wang; Guo-Hau Gou; Chia-Chun Wu; Hsain-Chung Shen; Leou-Chyr Lin; Ru-Yu Pan
Journal:  Biomed Res Int       Date:  2019-12-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.